Insulin pumps are having a moment, and this time it is not just Wall Street that is impressed—it is patients, payers, and, increasingly, competitors playing catch‑up.
Insulet’s Growth Streak Enters Double Digits
Insulet (PODD) closed 2025 like a company that never got the memo about “mature medtech,” delivering approximately 31% revenue growth in the fourth quarter to about 784 million dollars and crossing roughly 2.7 billion dollars for the full year. That marked its 10th consecutive year of more than 20% constant‑currency revenue expansion, an achievement more typical of hot software names than a maker of wearable insulin pumps.
The company’s Omnipod franchise did most of the heavy lifting, with Pod revenue growing in the low‑30% range and essentially accounting for the entire topline. Management highlighted another year of record new customer starts as patients continued migrating from multiple daily injections to automated delivery, a structural shift that still has considerable runway.
Margin Muscle in a Competitive Market
Insulet did not just grow; it grew with discipline. Gross margin in the fourth quarter expanded to roughly 72.5%, up about 40 basis points year over year, while full‑year gross margin finished around 71.6%, nearly 180 basis points higher than 2024. Operating income climbed to about 146 million dollars in Q4, or roughly 18.7% of revenue, with adjusted operating income moving in lockstep and advancing 30 to 40 basis points.investor.insulet+3
For 2025 as a whole, Insulet generated operating income in the mid‑400‑million‑dollar range and lifted operating margin by more than two percentage points, even as it invested in expanding capacity, innovation, and commercial reach. Free cash flow topped roughly 375 million dollars, offering investors the comforting reminder that rapid growth and cash generation are not mutually exclusive concepts.
Diabetes Care: From Niche to Strategic Asset
Insulet’s sustained growth says as much about the diabetes technology market as it does about the company. Management pointed to continued adoption of automated insulin delivery systems as physicians grow more comfortable prescribing pumps for a broader swath of patients, including those earlier in the disease course. With U.S. revenue growing in the high‑20% range and international sales advancing at an even faster clip in the fourth quarter, Omnipod is increasingly a global story rather than a North American niche. The U.S. market size is now at +27 million people with diabetes, where 4.88 million require daily insulin (2M Type 1, 2.88M Type 2). Only 20% of insulin dependent people with diabetes use a pump for insulin delivery. 80% rely on multiple daily injections (MDI).
Analysts now expect Insulet’s revenue to grow around the high‑teens to roughly 20% over the next year, slower than the recent breakneck pace but still robust for a company already above 2.5 billion dollars in sales. That leaves Insulet in the enviable position of arguing not whether it can grow, but whether it chooses to prioritize margin expansion, share gains, or both—an executive‑level version of having to pick just one dessert.
Modular Medical: The Challenger at the Gate
If Insulet represents the established growth franchise, Modular Medical (NASDAQ: MODD) is the challenger trying to re‑write the script on affordability and access. The company recently announced a 12 million dollar public offering priced at a premium to market, a notable show of confidence for a small‑cap medtech name in a still‑selective funding environment. The deal, led by Maxim Group, includes immediately exercisable warrants with a five‑year term, giving investors both capital appreciation potential and time to see the commercial story unfold.
Modular Medical’s pitch is elegantly simple: take lessons learned from prior pump platforms and engineer a system aimed at lower cost and easier use, broadening the market beyond today’s more complex devices. The company’s founder, Paul DiPerna, previously founded Tandem Diabetes (TNDM) and designed its t:slim pump, giving this new venture a pedigree that has not gone unnoticed among diabetes‑tech watchers. For a market where many patients still rely on injections for cost or usability reasons, a lower‑friction pump could be more than a niche—it could be an on‑ramp. The U.S. market size is now at +27 million people with diabetes, where 4.88 million require daily insulin (2M Type 1, 2.88M Type 2). Only 20% of insulin dependent people with diabetes use a pump for insulin delivery. 80% rely on multiple daily injections (MDI). HCPs fairly consistently indicated that about 25% of their MDI population are “almost pumpers”, meaning
that they have considered going on a pump, understand pump therapy benefits, but want something
simpler that doesn’t have all the “bells and whistles’, which is estimated to be ~$3 billion US market opportunity.
Two Paths, One Market: Insulet vs. Modular Medical
Investors now find themselves watching two very different approaches to the same problem: how to deliver insulin more effectively, with fewer trade‑offs for patients and payers.
| Company | Core focus | 2025/Recent scale | Strategic lever |
|---|---|---|---|
| Insulet (PODD) | Tubeless Omnipod AID systems | ~2.7B dollars revenue, 31% growth | Premium, high‑growth global platform |
| Modular Medical | Lower‑cost, simplified pump platform | Development‑stage, raised 12M dollars this week | Affordability, ease of use |
Insulet enjoys the advantages of scale, brand recognition, and a decade‑long track record of 20%‑plus growth, but it must continue innovating as competition intensifies and payers scrutinize every incremental dollar. Modular Medical (MODD), by contrast, is betting that a leaner design via their insulin pump called Pivot and a focus on lower cost could open new segments of the market—provided it can execute on manufacturing, regulatory milestones, and commercial rollout.
For Wall Street, the setup is familiar: a market leader proving the category’s durability and a newcomer seeking to expand the pie rather than simply slicing it thinner. For patients, it is a rare case where investors’ enthusiasm and clinical needs are aligned; more options in insulin delivery typically translate to better matches for individual lifestyles and budgets.
Outlook: An Expanding Field, Not a Zero‑Sum Game
Looking ahead, Insulet has guided to continued double‑digit growth, underpinned by ongoing conversion from injections, expansion into international markets, and further penetration of automated insulin delivery in both Type 1 and select Type 2 populations. The company’s strengthening balance sheet and rising free cash flow give it ample flexibility to invest in R&D, capacity, and potential partnerships, all while nudging margins higher over time.
Modular Medical (MODD), for its part, now has fresh capital and a longer runway to pursue its mission of making pump therapy more attainable. If the company can translate engineering expertise into a commercially viable, lower‑cost product, it may help expand the overall pump‑eligible population rather than simply vie for share within it—a scenario where the leader and the upstart both stand to benefit.
In a market long defined by trade‑offs—control versus convenience, innovation versus cost—the emerging narrative in diabetes tech is refreshingly constructive. Insulet is proving that scale and innovation can coexist, while Modular Medical (MODD) is trying to ensure that innovation does not become a luxury good, and that might be the kind of competition patients would not mind seeing a lot more of.
The Sources
Here is a clean, numbered source list with live links:
- Insulet Reports Fourth Quarter and Full Year 2025 Results (Insulet IR)
https://investor.insulet.com/news/news-details/2026/Insulet-Reports-Fourth-Quarter-and-Full-Year-2025-Results/default.aspx[investor.insulet] - Insulet Reports Fourth Quarter and Full Year 2025 Results (Yahoo Finance syndication)
https://finance.yahoo.com/news/insulet-reports-fourth-quarter-full-120000955.html[finance.yahoo] - Insulet Corporation Q4 2025 Earnings Call Summary
https://finance.yahoo.com/news/insulet-corporation-q4-2025-earnings-133000560.html[finance.yahoo] - Insulet Corp (PODD) Q4 2025 Earnings Call Highlights
https://finance.yahoo.com/news/insulet-corp-podd-q4-2025-190048367.html[finance.yahoo] - Insulet (NASDAQ:PODD) Surprises With Q4 CY2025 Sales
https://finance.yahoo.com/news/insulet-nasdaq-podd-surprises-q4-120738996.html[finance.yahoo] - Insulet Corporation Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025
https://www.marketscreener.com/news/insulet-corporation-reports-earnings-results-for-the-fourth-quarter-and-full-year-ended-dece-xxxx[marketscreener] - Insulet Q4 2025 Slides: Revenue Soars 31%, Stock Jumps on Strong 2026 Outlook
https://www.investing.com/news/company-news/insulet-q4-2025-slides-revenue-soars-31-stock-jumps-on-strong-2026-outlook-93CH-4511[investing] - Insulet Stock Rises Before Hours on Q4 Beats, 31% Sales Growth
https://www.drugdeliverybusiness.com/insulet-q4-2025-beats-stock-growth/[drugdeliverybusiness] - Insulet Boosts Buyback, Posts 31% 2025 Revenue Growth
https://www.stocktitan.net/sec-filings/PODD/8-k-insulet-corp-reports-material-event-8b015c630092.html[stocktitan] - Modular Medical Announces 12.0 Million Public Offering Priced at a Premium to Market
https://finance.yahoo.com/news/modular-medical-announces-12-0-142700002.html[finance.yahoo] - Modular Medical Announces 12.0 Million Public Offering Priced at a Premium to Market (press release host)
https://www.biospace.com/press-releases/modular-medical-announces-12-0-million-public-offering-priced-at-a-premium-to-market[biospace] - Modular Medical Prices 12M Stock and Warrant Sale
https://www.stocktitan.net/news/MODD/modular-medical-announces-12-0-million-public-offering-priced-at-a-94hlmxlvuulh.html[stocktitan] - Modular Medical Begins Production of Insulin Pump Components
https://www.streetinsider.com/Corporate+News/Modular+Medical+begins+production+of+insulin+pump+components/25943724.html[streetinsider] - Modular Medical Achieves Key Manufacturing Milestone for Pivot Tubeless Insulin Patch Pump
https://nationaltoday.com/us/ca/san-diego/news/2026/02/05/modular-medical-achieves-key-manufacturing-milestone-for-pivot-tubeless-insulin-patch-pump[nationaltoday]
